Peter Kohler, MD
Medical Oncology · Traverse City, MINPI 1477520872
Payments from drug & device makers
What this record shows
This record is dominated by education: $41 of the $41 with a category attached, or 100.0%. 3 manufacturers reported payments, led by Merck at 44.0% of the total. That places this record below the midpoint for medical oncology clinicians in MI, where the typical reported total is $1,832.
Across 3 payments — averaging $13.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$18
- Gilead$12
- E.r. Squibb & Sons, L.L.C.$11
Across 18 payments — averaging $6075.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$99K
- Pfizer$10K
What the payments were for
- Education$41100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 1 | $18 |
| Gilead | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
How this compares
$41 in reported general payments places this provider in the 15th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 219 | $379,591 |
| XtandiEnzalutamide | 26 | $373,851 |
| CabometyxCabozantinib S-Malate | 14 | $364,426 |
| LynparzaOlaparib | 11 | $190,084 |
| OrgovyxRelugolix | 22 | $57,447 |
| Anastrozole | 296 | $10,551 |
| Tamoxifen Citrate | 66 | $2,538 |
| Prednisone | 129 | $1,970 |
| Prochlorperazine Maleate | 51 | $1,023 |
| Dexamethasone | 46 | $380 |
| Levothyroxine Sodium | 37 | $356 |
| Ondansetron Hcl | 58 | $270 |
| Letrozole | 20 | $263 |
| Oxybutynin Chloride | 24 | $234 |
| Ondansetron OdtOndansetron | 20 | $217 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Traverse City
- Harry ErbaAnn Arbor$1.1M
- Philip PhilipDetroit$494K
- Shirish GadgeelDetroit$413K
- Patricia Lo RussoDetroit$322K
- Ammar SukariDetroit$273K
- Sami BrakeGrand Rapids$251K
- Frank WeinbergAnn Arbor$195K
- Wajahat KhanGrosse Pointe Woods$190K
- Charles SchifferDetroit$165K
- Francis WordenAnn Arbor$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.